Beating cancer with food
Updated Feb 17, 2021, 12:05 am IST
Dr Shubham Pant’s recent book gives details on how food and one’s diet can combat cancer
Book cover
Cancer is now the fourth leading cause of death in India. So the most pressing question today is what are you doing to lower your risk? In FOOD MATTERS: The Role Your Diet Plays in the Fight Against Cancer, author Dr Shubham Pant asks readers to ‘focus on the mundane solutions’.
Oncologist at the University of Texas MD Anderson Cancer Center in Houston, Texas, Dr Pant recommends eating a good diet, staying a healthy weight and considering other lifestyle interventions to keep cancer at bay. Citing case studies in the book, Dr Pant also suggests how patients diagnosed with and recovering from cancer can best manage their nutritional needs.
Published 14 February 2021
(UroToday.com) Members of the forkhead transcription factor (FOX) family are important mediators of embryonic development and are known to be altered in a variety of cancers. However, to date, the functional role of
FOXF1 in bladder tumorigenesis and progression has not been clearly characterized. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Anirban Mitra and colleagues from the MD Anderson Cancer Center reported results of their study investigating the clinical implications of differential
FOXF1 expression in bladder cancer, and potential mechanisms by which its alteration can lead to tumor metastasis.
For this study, whole-genome expression profiling was performed on paired primary tumors and nodal metastases from a radical cystectomy discovery cohort using Illumina HT12 v3-4 BeadChip arrays to identify
Published 13 February 2021
(UroToday.com) The ASCO GU 2021 Genitourinary Cancers Symposium annual meeting included an invited discussion from Dr. Arlene Siefker-Radtke discussing “Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma” and “EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.”
Dr. Siefker-Radtke notes that we now have level 1 evidence with overall survival benefit for enfortumab vedotin in the 3
rd line for metastatic urothelial carcinoma. EV-301 (NCT03474107) is a global, open-label phase III study of enfortumab vedotin versus chemotherapy conducted in patients with locally advanced or metastatic urothelial carcinoma who had received prior platinum-containing chemotherapy and had disease progression during or after PD-1/L1 in
Feb 15, 2021
Genomic classifier helps weed out men less likely to benefit from added hormone Tx
To help clinicians determine which men with recurrent prostate cancer after surgery will benefit from the addition of hormone therapy to salvage radiotherapy (sRT), researchers validated the Decipher genomic classifier, demonstrating that it was independently associated with the risk of distant metastases (DM), prostate cancer-specific mortality (PCSM), and overall survival (OS).
Importantly, these results suggest that not all men with biochemically recurrent prostate cancer will derive the same benefits from the addition of hormone therapy to sRT.
“To date and to our knowledge, no multigene expression biomarker has been rigorously validated as a prognostic or predictive test in patients with prostate cancer who are receiving radical therapy,” Felix Y. Feng, MD, of the Helen Diller Family Comprehensive Cancer Center, San Francisco, and colleagues observed. “[These] findings add t
Klatskin Tumor Treatment newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.